Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vital Farms Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Vital Farms Inc trades at $11.45 (market cap $496.50M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 59.6× Vital Farms Inc's market cap. Which is the better fit depends on your goals.
| ALNY | VITL | |
|---|---|---|
Market Cap | $29.60B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $52.41 |
52-Week Low | $205.48 | $8.28 |
Enterprise Value | $27.56B | $583.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Vital Farms (VITL) trades at $11.52, up 2.31% today, amid bearish technical signals and challenging fundamentals. The stock shows oversold conditions with RSI at 29.21, while recent Q2 2026 results revealed a $0.47 per share loss despite beating revenue estimates. The company secured $125 million in financing to navigate industry oversupply pressures and elevated costs affecting profitability.
While analyst consensus remains positive with a $13.00 price target and no sell ratings, near-term headwinds from margin compression and net cash outflows pose significant risks. The stock's valuation appears reasonable with P/E of 11.77 and P/S of 0.67, but investors should monitor execution on cost management and revenue stabilization for sustainable recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
